Paracetamol IV Market Size, Growth, Trends | Report 2022-2030
The global paracetamol IV market was valued at USD 700.3 million in 2021 and it is predicted to surpass around USD 994.41 million by 2030 with a CAGR of 3.97% from 2022 to 2030
Report Highlights
The rising prevalence of chronic disorders that requires pain management is expected to facilitate the growth of the industry during the forecast period. The enhanced usage of acetaminophen to reduce the dependence on opioids for pain management is projected to accelerate the growth in demand for paracetamol IV. The IV paracetamol is a stable acetaminophen form and is intended for mild to moderate pain management. It is used over other NSAIDs to treat patients with a history of peptic ulcers and asthma, as it lacks interference with the function of platelets.
Rising cases of patients reporting postoperative pain are expected to propel the demand for drugs and products with fewer side effects. As per the article published in the International Journal of Surgery, in March 2022, 77% - 83% of patients in the U.S., 80% of patients in Thailand, 76% of patients in Sweden, and 29.5% of patients in Germany reported severe to moderate postoperative pain. The IV paracetamol is intended for usage in the treatment of acute postoperative pain and during the surgeries, such as orthopedic, dental, and gynecological. A rise in the number of surgeries performed and patients experiencing post-operative pain is expected to create a high product demand in the years to come. However, the availability of multiple generic products is expected to hinder the industry during the forecast period.
For instance, in December 2020, Sandoz International GmbH launched a generic acetaminophen injection in the U.S. The product will be available in 10 mg/mL concentration, in a 100 mL vial for the treatment of mild to moderate in conjunction with opioid analgesics for pediatric patients. Key players operating in the global industry are following various strategic initiatives for business expansion and to gain a competitive edge over others. For instance, in December 2021, Leucadia Pharmaceuticals launched and announced the availability of a generic acetaminophen injection, which is an FDA-approved generic that corresponds to the acetaminophen injection manufactured by Mallinckrodt Pharmaceuticals.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 700.3 million |
| Revenue Forecast by 2030 | USD 994.41 million |
| Growth rate from 2022 to 2030 | CAGR of 3.97% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Indication, application, end-use, region |
| Companies Covered | Mallinckrodt (Mallinckrodt Pharmaceuticals); Cipla Inc.; Lupin; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma; Sun Pharmaceutical Industries Ltd.; Novartis AG; Pfizer Inc.; Abbott; Sanofi; Bristol-Myers Squibb Company |
Indication Insights
Based on indications, the global industry has been further bifurcated into pain and pyrexia (fever). The pain indication segment dominated the global industry in 2021 and accounted for the maximum share of more than 67.03% of the overall revenue. The high share of this segment was attributed to the effectiveness and rapid action of paracetamol being administered intravenously in pain management. A single dose of paracetamol given intravenously is effective in relieving pain for around 4 hours for about 37% of patients with acute post-operative pain. Moreover, paracetamol IV is effective and safe for the treatment of postoperative pain in both children and adults.
This, in turn, makes it more feasible to be used for a large patient pool. In addition, the product is considered a first-line treatment for acute pain and chronic pain as it is a non-addictive pain treatment. On the other hand, the pyrexia (fever) indication segment is projected to expand at the fastest growth rate during the forecast period. This can be attributed to the acceptance of paracetamol IV as the first line of treatment for fever and pain in pediatric patients. With the increasing pediatric population, the usage of paracetamol through infusion is also rising. However, the product is only used for short-term treatment, which, in turn, limits its adoption.
Application Insights
Based on applications, the global industry has been further categorized into surgical and non-surgical. The surgical application segment dominated the global industry in 2021 and accounted for the maximum share of more than 63.55% of the overall revenue. The high share of this segment can be credited to the increased usage of paracetamol IV for the treatment of post-operative pain and quicker relief from fever. After surgery, most patients go through acute and mild pain, which, in turn, requires early treatment. With the increasing volumes of surgeries performed and the need to provide relief within a short duration of time, the adoption of paracetamol IV is projected to rise.
On the other hand, the non-surgical application segment is expected to register the fastest growth rate during the forecast period. The fastest growth of the non-surgical segment can be attributed to the increasing awareness among the population about the treatment of discomfort and fever-related symptoms. A wide range of paracetamol IV products is available in syringe form, which makes it easy to use and offers a quick effect. For instance, a liquid injectable form comprising acetaminophen, hydroxyethyl starch, and at least one osmolality agent is widely accepted as an infusion.
End-use Insights
Based on end-uses, the global industry has been further sub-segmented into hospitals, clinics, and others. The hospitals end-use segment dominated the overall industry in 2021. The segment accounted for the maximum share of more than 52.47% of the global revenue in the same year. It is projected to expand further at a significant growth rate during the forecast period maintaining its leading position. The dominance of this segment can be attributed to the increasing number of surgeries carried out in hospitals on account of the presence of qualified and specialized healthcare professionals.
The need for rapid relief from post-operative surgeries is further driving the growth of the segment. The clinics end-use segment is expected to account for the second-highest revenue share by 2030 on account of the increasing cases of short-term treatment of fever during urgent need to induce hypothermia. There is a high demand for treatments in clinics due to the easy access for remotely located patients. Moreover, the rising number of technological advancements and adoption of types of equipment in clinics is further spurring the growth of the segment.
Regional Insights
North America dominated the global sector in 2021 and accounted for the maximum share of more than 40.23% of the overall revenue. The dominance of the market is attributed to the popularity of paracetamol IV as it is one of the most frequently used medications with sales surpassing millions of doses every year. The formulation is highly used in hospitals and healthcare systems to treat patients with acute to mild pain. The use of the intravenous drug in emergency surgery, cohorts where the risk of morbidity can be reduced by adequately maintaining hemodynamics is further fueling the growth of the sector in this region.
Asia Pacific, on the other hand, is projected to grow at the fastest CAGR during the forecast period on account of the increasing prevalence of chronic diseases, rapid growth in the geriatric population, and the presence of key industry participants. Moreover, high product demand, due to lower costs associated with the drug and quick relief offered in postoperative pain, will drive the region’s growth over the coming years. For instance, according to the UNFPA, the older population in Asia is rising at an unprecedented rate, and it is expected to triple reaching 1.3 billion by 2050. Key players in the region include Cipla Inc., Sun Pharmaceutical Industries Ltd., and Lupin.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Paracetamol IV Market
5.1. COVID-19 Landscape: Paracetamol IV Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Paracetamol IV Market, By Indication
8.1. Paracetamol IV Market, by Indication, 2022-2030
8.1.1 Pain
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Pyrexia (Fever)
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Paracetamol IV Market, By Application
9.1. Paracetamol IV Market, by Application, 2022-2030
9.1.1. Surgical
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Non-surgical
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Paracetamol IV Market, By End-use
10.1. Paracetamol IV Market, by End-use, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Paracetamol IV Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Mallinckrodt (Mallinckrodt Pharmaceuticals)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cipla Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Lupin
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Dr. Reddy's Laboratories Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Aurobindo Pharma
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sun Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pfizer, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Abbott
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sanofi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers